Roca Therapeutics is a biotechnology company that designs small molecules addressing dedicated pathobiological mechanisms (M2 Macrophages driven immunosuppression and resistant angiogenesis) recently linked to indications such as Uveal Melanoma as well as Renal Cell Carcinoma and Head and Neck Squamous Cell Carcinoma.
Roca Therapeutics has 1 recorded funding round in the Tech.eu database (amounts undisclosed). Based in Nice, France; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-09-26 | Other | — |
| BPI,Eurobiomed Grand Sud,PACA Cancéropôle,Southern Regional council,UCA |
| View deal → |
